CA-TII
26.4.2021 12:42:13 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced that its Quantum Research Centre (QRC) has developed the first simulation version of 'Qibo', a versatile open-source quantum computing programming framework, in collaboration with researchers from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005389/en/
The development follows a series of rapid announcements at TII since the first ATRC board meeting in August 2020.
TII strives to create innovation for a better world. The development of an open-source programming framework will have compelling benefits for the global research community.
Qibo is designed to support quantum algorithms across different computer systems, including support to hardware accelerators such as graphics processing units (GPUs) and multiple quantum devices. This versatility makes Qibo easy to use for quantum programming and accelerates research and applications. Written in programming languages such as Python and C/C++, Qibo is the entry point for a full stack programming platform, able to run quantum algorithms across different quantum computers and simulators.
Qibo is a joint project by Quantum Research Centre; Qilimanjaro Quantum Tech, the Barcelona-based quantum computing company; and researchers at other global centres. TII’s Quantum Research Centre team is led by Chief Researcher Prof José Ignacio Latorre. The first release of Qibo was published in September 2020, with the final version set for launch within the next two years.
Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of Advanced Technology Research Council (ATRC), said: “The fact that Qibo is open-source will be a significant advantage to the world of programming and marks a major contribution to the research community and the advancement of scientific inquiry. Initial benchmark studies that show Qibo outperforming other computing languages is a clear indication of the quality of research currently being undertaken at Quantum Research Centre at Technology Innovation Institute."
Prof José Ignacio Latorre, Chief Researcher at Quantum Research Centre, said: “We are committed to innovation that transcends boundaries. The quantum advantage in computing will offer notable benefits to broader society, ranging from life-sciences, artificial intelligence, and finance.”
QRC is one of seven initial dedicated research centres that are part of TII. The Qibo code published in the research paper can be accessed via a GitHub link [https://qibo.science/ ].
About Technology Innovation Institute (TII)
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
About Quantum Research Centre (QRC)
Quantum Research Centre – at Technology Innovation Institute (TII) – has been created to develop world-class quantum-theoretical and experimental research by building and operating the first quantum computer in the MENA region while advancing quantum communications and quantum sensors. The Centre aims to develop pioneering technologies backed by the expertise of an international team of leading researchers, dedicated to achieving a ‘Quantum Advantage’ which will transform the power and scope of computers.
For more information, visit https://quantum.tii.ae/
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter:
https://twitter.com/TIIuae
Instagram:
https://www.instagram.com/tiiuae/
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005389/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
